Buyer being a relative term.
BioTime (NYSEMKT:BTX) agreed to take over the program, but Geron wouldn't get anything in return. The proposal is basically a spinout combining BioTime's and Geron's stem-cell assets. BioTime also plans to contribute $40 million worth of its stock, which would presumably be sold to fund the program. The new entity also plans to sell shares to raise additional capital.
Geron's shareholders would own 21.4% of the new company, which could increase to 45% if they purchase additional shares in the spinoff. BioTime is also willing to give Geron's shareholders warrants to buy shares of BioTime.
BioTime proposed the deal in a letter to Geron's shareholders encouraging them to push the board into approving the transaction. Not said, but implied, is that BioTime has probably run the deal (or something similar) by Geron's board, which must have rejected the offer. On Friday, Geron acknowledged BioTime's proposal and said the board would consider it.
My guess is the board won't accept the public offer. Geron's management decided that the cancer program is the most important thing, and this deal doesn't bring in any cash to help the program. Canceling the stem cell program certainly helped with the cash burn, but Geron is still running five phase 2 clinical trials and only had $122 million in the bank at the end of the second quarter.
Getting cash for the program should be the No. 1 priority for investors. If you own Geron at this point, it should primarily be because you have confidence in the cancer program.
Of course, it's been a year and none of the big boys like GlaxoSmithKline (NYSE:GSK), Pfizer (NYSE:PFE), and Teva Pharmaceuticals (NYSE:TEVA) -- which all have varying degrees of stem cell programs -- have stepped up to purchase the assets. At some point, getting something, even from a podunk biotech, is better than nothing from a shareholder's perspective.
Fool contributor Brian Orelli has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
5 Biotech Buyout Candidates for 2018
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
3 Stocks to Hold for the Next 20 Years
If you're looking for long-term stocks to buy, check out this trio that look primed for outperformance.
2 Reasons Geron Corporation Took a Pounding in November
Can these concerns be overlooked?